Liangpeng Yang

1.0k total citations
29 papers, 698 citations indexed

About

Liangpeng Yang is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Liangpeng Yang has authored 29 papers receiving a total of 698 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Molecular Biology and 10 papers in Immunology. Recurrent topics in Liangpeng Yang's work include Cancer-related Molecular Pathways (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and DNA Repair Mechanisms (5 papers). Liangpeng Yang is often cited by papers focused on Cancer-related Molecular Pathways (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and DNA Repair Mechanisms (5 papers). Liangpeng Yang collaborates with scholars based in United States, China and Türkiye. Liangpeng Yang's co-authors include Chou‐Zen Giam, Huijun Zhi, Hsiu-Ming Shih, Hampartsoum B. Barsoumian, James W. Welsh, Yun Hu, María Angélica Cortez, J. M. Trujillo, Dawei Chen and Ahmed Younes and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Journal of Virology.

In The Last Decade

Liangpeng Yang

26 papers receiving 688 citations

Peers

Liangpeng Yang

IMMUN

ONCOL

EEBS

ACS

Yoshihiro Koya Japan

Shingo Nakahata Japan

Remy Thomas Qatar

Maiko Morita Japan

Shajedul Islam Japan

H Igarashi Japan

Julita Ramírez United States

N. Razavian United States

Denis L’Abbé Canada

Jonathan Trujillo United States

Yoshihiro Koya Japan

Liangpeng Yang

495 ×1.6

IMMUN

186 ×0.7

ONCOL

257 ×1.0

312 ×2.3

EEBS

318 ×2.4

ACS

Citations per year, relative to Liangpeng Yang Liangpeng Yang (= 1×) peers Yoshihiro Koya

Countries citing papers authored by Liangpeng Yang

Since Specialization

Citations

This map shows the geographic impact of Liangpeng Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liangpeng Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liangpeng Yang more than expected).

Fields of papers citing papers by Liangpeng Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liangpeng Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liangpeng Yang. The network helps show where Liangpeng Yang may publish in the future.

Co-authorship network of co-authors of Liangpeng Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Liangpeng Yang. A scholar is included among the top collaborators of Liangpeng Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liangpeng Yang. Liangpeng Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pifer, Phillip M., Liangpeng Yang, Manish Kumar, et al.. (2023). FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner. Clinical Cancer Research. 30(1). 187–197. 13 indexed citations

Hu, Yun, Sébastien Paris, Hampartsoum B. Barsoumian, et al.. (2022). Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer. Journal of Nanobiotechnology. 20(1). 417–417. 24 indexed citations

Molkentine, David, Jessica M. Molkentine, Kathleen A. Bridges, et al.. (2021). p16 Represses DNA Damage Repair via a Novel Ubiquitin-Dependent Signaling Cascade. Cancer Research. 82(5). 916–928. 22 indexed citations

Hu, Yun, Sébastien Paris, Hampartsoum B. Barsoumian, et al.. (2021). A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model. Journal of Nanobiotechnology. 19(1). 416–416. 25 indexed citations

Hu, Yun, James W. Welsh, Sébastien Paris, et al.. (2021). 575 Dual blockade of LAG3 and TIGIT improves the treatment efficacy of a nanoparticle-mediated immunoradiation in anti-PD1 resistant lung cancer in mice. SHILAP Revista de lepidopterología. A604–A604. 2 indexed citations

Chen, Dawei, Hampartsoum B. Barsoumian, Liangpeng Yang, et al.. (2020). SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti–PD-1–Resistant Model of Non–Small Cell Lung Cancer. Cancer Immunology Research. 8(7). 883–894. 63 indexed citations

Younes, Ahmed, Hampartsoum B. Barsoumian, Duygu Sezen, et al.. (2020). Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity. Translational Oncology. 14(2). 100983–100983. 20 indexed citations

Chen, Dawei, Hampartsoum B. Barsoumian, Grant M. Fischer, et al.. (2020). Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity. Journal for ImmunoTherapy of Cancer. 8(1). e000289–e000289. 69 indexed citations

Molkentine, Jessica M., David Molkentine, Kathleen A. Bridges, et al.. (2020). Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. International Journal of Radiation Biology. 97(8). 1121–1128. 29 indexed citations

10.

Chen, Dan, Liangpeng Yang, Ahmed Younes, et al.. (2020). SHP-2 and PDL1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD1-resistant Model of Non-small-cell-lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 108(3). S91–S91.

11.

Kumar, Manish, Liangpeng Yang, David Molkentine, et al.. (2017). BAP1 Is a Novel Target in HPV-Negative Head and Neck Cancer. Clinical Cancer Research. 24(3). 600–607. 20 indexed citations

12.

Woo, Sang Hyeok, Vlad C. Sandulache, Liangpeng Yang, & Heath D. Skinner. (2014). Evaluating Response to Metformin/Cisplatin Combination in Cancer Cells via Metabolic Measurement and Clonogenic Survival. Methods in molecular biology. 1165. 11–18. 6 indexed citations

13.

Sandulache, Vlad C., Liangpeng Yang, & Heath D. Skinner. (2014). Use of Biguanides to Improve Response to Chemotherapy. Methods in molecular biology. 1165. 3–9.

14.

Zhi, Huijun, et al.. (2011). NF-κB Hyper-Activation by HTLV-1 Tax Induces Cellular Senescence, but Can Be Alleviated by the Viral Anti-Sense Protein HBZ. PLoS Pathogens. 7(4). e1002025–e1002025. 112 indexed citations

15.

Yang, Liangpeng, et al.. (1999). Use of novel plasmid constructs to demonstrate fludarabine triphosphate inhibition of nucleotide excision repair of a site-specific 1,2-d(GpG) intrastrand cisplatin adduct.. International Journal of Oncology. 15(6). 1177–83. 6 indexed citations

16.

Helke, Cinda J. & Liangpeng Yang. (1996). Interactions and Coexistence of Neuropeptides and Serotonin in Spinal Autonomic Systems^a. Annals of the New York Academy of Sciences. 780(1). 185–192. 11 indexed citations

17.

Chiou, Yuan‐Yow, et al.. (1995). Peritonitis in children being treated with continuous ambulatory peritoneal dialysis. CAPD Team.. 36(3). 176–183.

18.

Yang, Liangpeng & J. M. Trujillo. (1990). Biological characterization of multidrug-resistant human colon carcinoma sublines induced/selected by two methods.. PubMed. 50(11). 3218–25. 34 indexed citations

19.

Trujillo, José M., et al.. (1990). Metronidazole enhances the cytotoxic synergism produced by the combination of 1-beta-arabinofuranosylcytosine and cis-diamminedichloroplatinum.. PubMed. 9(6). 1751–6. 2 indexed citations

20.

Trujillo, José M. & Liangpeng Yang. (1989). Synergism of 1-beta-D-arabinofuranosylcytosine and cis-diamminedichloroplatinum in their lethal efficacies against seven established cancer cell lines of gastrointestinal origin.. PubMed. 9(1). 197–201. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact